Compare TTI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTI | LBRX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | 2025 |
| Metric | TTI | LBRX |
|---|---|---|
| Price | $6.01 | $38.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $10.88 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 2.2M | 313.2K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $9.58 | N/A |
| P/E Ratio | $35.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.87 | $15.55 |
| 52 Week High | $12.54 | $50.16 |
| Indicator | TTI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 43.20 |
| Support Level | $5.64 | $37.99 |
| Resistance Level | $6.31 | $41.58 |
| Average True Range (ATR) | 0.33 | 2.87 |
| MACD | 0.03 | -0.39 |
| Stochastic Oscillator | 38.89 | 8.47 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.